Latest Regulatory Risks News

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

European Lithium Ltd has released compelling assay results from historical deep diamond drilling at its Tanbreez Rare Earth Project in Greenland, confirming high-grade rare earth oxides and significant gallium concentrations that support potential resource expansion.

Coronado Global Resources Inc. posted a $96.2 million net loss for Q1 2025, reflecting weak metallurgical coal prices and ongoing liquidity challenges. The company is navigating covenant waivers and pursuing refinancing amid market uncertainty.

Macquarie Group reported a 5% rise in full-year net profit to A$3.715 billion for FY25, driven by growth across its diversified businesses and a solid capital position. The group’s assets under management reached A$941 billion, supported by strong home loan and deposit growth.

PointsBet Holdings Limited has announced a scheme meeting for shareholders to vote on its proposed $1.06 per share acquisition by MIXI Australia, with an independent expert deeming the offer fair and reasonable amid a competing bid from betr Entertainment.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Spenda Limited has responded to an ASX price query following a notable rise in its share price and trading volume, denying any undisclosed material information while confirming ongoing confidential negotiations for virtual card and funding services.

Westpac Banking Corporation reported a modest 1% decline in net profit to AUD 3.317 billion for the six months ended March 2025, maintaining its interim dividend and advancing key digital and sustainability initiatives.

VDM Group Limited faces suspension on the ASX due to a joint venture dispute in Angola, halting exploration activities. The company is pivoting towards new critical minerals projects in Australia to restore trading and investor confidence.

St Barbara Limited confirms a robust Simberi Expansion Project with a 13-year life of mine plan delivering 2.2 million ounces of gold and annual production exceeding 220,000 ounces from FY28. The project’s strong economics and infrastructure upgrades position it as a significant growth driver amid regulatory uncertainties.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Donaco International reported a modest revenue and EBITDA decline in Q3 FY2025 but strengthened its cash reserves. Meanwhile, the company agreed to a full acquisition scheme at a significant premium, setting the stage for shareholder decisions amid regulatory uncertainties.